Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy
Clinical and Translational Medicine · 2025-05 · 15 (5)
DOI: 10.1002/ctm2.70345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 25.05.2025. Verfasst von Simin Xiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Program of Zhejiang Province Natural Science Foundation of China, Medical Interdisciplinary Innovation Program 2024, Zhejiang University School of Medicine.
Abstract (Originalsprache)
Persistent stimulation from cancer antigens leads to T lymphocytes (T cells) exhaustion, with up‐regulated expression of co‐inhibitory receptors, including programmed death‐1 (PD‐1), cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), lymphocyte‐activation gene 3 (LAG‐3), T cell immunoglobulin and mucin domain 3 (TIM‐3) and T cell immunoreceptor with Ig and ITIM domains (TIGIT). These receptors collectively impair T cell function via distinct molecular pathways, contributing to immune evasion and cancer progression. This review highlights the therapeutic promise of immune checkpoint inhibitors (ICIs) in reversing T cell exhaustion while delving into the complex molecular processes and functional works of these important co‐inhibitory receptors in tumourigenesis. Additionally, we examine the synergistic effects of combining ICIs with other therapeutic strategies, which can enhance anti‐tumour efficacy. Finally, the clinical implications of bispecific antibodies are highlighted, representing a promising frontier in cancer immunotherapy, that could revolutionise treatment paradigms while improving patient outcomes. Highlights This review discusses five major co‐inhibitory receptors (PD‐1, CTLA‐4, LAG‐3, TIM‐3 and TIGIT) and their related mechanisms of T cell exhaustion in the tumour environment. We also discuss the clinical application of checkpoint inhibitors (ICIs) in cancer immunotherapy. The potential of bispecific antibodies (BsAbs) in cancer immunotherapy is highlighted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
ORCID-Profile: Junfen Xu
Förderung
- National Natural Science Foundation of China
- Key Program of Zhejiang Province Natural Science Foundation of China
- Medical Interdisciplinary Innovation Program 2024, Zhejiang University School of Medicine
- National Natural Science Fund for Young Scientists Fund Program C
Zitieren
APA
Xiang, S., Li, S., & Xu, J. (2025). Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy. Clinical and Translational Medicine, 15(5). https://doi.org/10.1002/ctm2.70345
Vancouver
Xiang S, Li S, Xu J. Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy. Clinical and Translational Medicine. 2025;15(5). doi:10.1002/ctm2.70345
BibTeX
@article{Xiang2025,
author = {Xiang, Simin and Li, Sen and Xu, Junfen},
title = {Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy},
journal = {Clinical and Translational Medicine},
year = {2025},
volume = {15},
number = {5},
doi = {10.1002/ctm2.70345}
}
EUVIMED